^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    KIR2DL1 (Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Long Cytoplasmic Tail 1)

    i
    Other names: KIR2DL1, Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Long Cytoplasmic Tail 1, CD158A, P58.1, Killer Cell Immunoglobulin-Like Receptor, Two Domains, Long Cytoplasmic Tail, 1, P58 Natural Killer Cell Receptor Clones CL-42/47.11, Killer Cell Immunoglobulin-Like Receptor 2DL1, Natural Killer-Associated Transcript 1, P58.1 MHC Class-I-Specific NK Receptor, CD158 Antigen-Like Family Member A, MHC Class I NK Cell Receptor, P58 NK Receptor CL-42/47.11, NKAT-1, Cl-42, Nkat1, 47.11, NKAT1, P58 Killer Cell Inhibitory Receptor KIR-K64, P58 NK Cell Inhibitory Receptor NKR-K6, Killer Inhibitory Receptor 2-2-1, KIR2DL Protein, CD158a Antigen, KIR2DL1/3DL2, KIR-K64, KIR2DL3, KIR221, NKAT
    Associations

    News

    Trials
    4d
    KIR AA individuals possess strong inhibitory KIR alleles alongside HLA ligands that are protective against leukemia in the Chinese population. (PubMed, Front Genet)
    These data suggest that KIR AA individuals possess strong inhibitory interactions of KIR alleles and HLA, arming KIR AA + NK cells to meditate stronger alloreactivity and cytotoxicity against leukemia cells with lowered HLA expression. Our findings may provide valuable insights into leukemia pathogenesis and better understanding of the immune mechanisms.
    Journal
    |
    KIR3DL2 (Killer Cell Immunoglobulin Like Receptor Three Ig Domains And Long Cytoplasmic Tail 2) • HLA-B (Major Histocompatibility Complex, Class I, B) • KIR3DL1 (Killer Cell Immunoglobulin Like Receptor, Three Ig Domains And Long Cytoplasmic Tail 1) • KIR2DL3 (Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Long Cytoplasmic Tail 3) • KIR2DS4 (Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Short Cytoplasmic Tail 4) • KIR2DL1 (Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Long Cytoplasmic Tail 1) • KIR2DS2 (Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Short Cytoplasmic Tail 2)
    1m
    Resting-state spatial statistics of NK cell receptors may improve early signal discrimination. (PubMed, Biophys J)
    Modeling shows when NKG2D and KIR2DL1 clusters are disjoint in the resting state, these clusters help NK cells to discriminate between target cells expressing low and high levels of the activating cognate ligand, whereas, when the NKR clusters show high degree of overlap it prevents NK cells from differentiating healthy from diseased target cells. Therefore, the spatial statistics of submicron scale clusters of activating and inhibitory NKRs at the resting state provides an additional layer of control for signal discrimination in NK cells.
    Journal
    |
    KIR2DL1 (Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Long Cytoplasmic Tail 1) • NKG2D (killer cell lectin like receptor K1)
    3ms
    Establishment and Multidimensional Characterization of a Novel EBV-negative Human Type Ⅰ Natural Killer T Cell Line NKT617. (PubMed, Lab Invest)
    We report the first EBV-negative human type I NKT cell line, NKT617, which offers significant potential for studying NKT cell development and advancing chimeric antigen receptor based therapies. This cell line serves as a valuable tool for exploring NKT cell biology and developing targeted immunotherapies.
    Preclinical • Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IL2 (Interleukin 2) • NCAM1 (Neural cell adhesion molecule 1) • CD2 (CD2 Molecule) • TRB (T Cell Receptor Beta Locus) • KIR2DL1 (Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Long Cytoplasmic Tail 1)
    6ms
    Expression of metabolic genes in NK cells is associated with clinical outcomes in patients with severe COVID-19: a brief report. (PubMed, Front Cell Infect Microbiol)
    SIRT1, HIF1A, and GLUT1 were upregulated in deceased patients (P < 0.05). In conclusion, we demonstrate that NK cells from patients with severe COVID-19 exhibit increased functional markers and dysregulated metabolic gene expression associated with clinical outcomes.
    Clinical data • Journal
    |
    IFNG (Interferon, gamma) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1) • LAMP1 (Lysosomal Associated Membrane Protein 1) • GZMB (Granzyme B) • SOCS1 (Suppressor Of Cytokine Signaling 1) • SIRT1 (Sirtuin 1) • KIR2DL1 (Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Long Cytoplasmic Tail 1) • SLC2A1 (Solute Carrier Family 2 Member 1)
    6ms
    Clinicopathological features and prognosis of aggressive natural killer-cell leukemia: an analysis of 27 cases (PubMed, Zhonghua Bing Li Xue Za Zhi)
    Tumor cells exhibit significant morphological variation, and bone marrow infiltration patterns are diverse. Accurate recognition, early diagnosis, and timely chemotherapy are critical to improving the prognosis of patients with ANKL.
    Retrospective data • Journal • IO biomarker
    |
    CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • CD5 (CD5 Molecule) • GZMB (Granzyme B) • KIR3DL1 (Killer Cell Immunoglobulin Like Receptor, Three Ig Domains And Long Cytoplasmic Tail 1) • CD2 (CD2 Molecule) • KIR2DS4 (Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Short Cytoplasmic Tail 4) • B3GAT1 (Beta-1,3-Glucuronyltransferase 1) • KIR2DL1 (Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Long Cytoplasmic Tail 1) • KIR2DS2 (Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Short Cytoplasmic Tail 2)
    6ms
    A comprehensive analysis of the tryptophan metabolism-related gene signature to predict the prognosis of esophageal squamous cell carcinoma based on multi-omics. (PubMed, Front Mol Biosci)
    High-risk patients showed poorer overall survival (OS), distinct immune cell infiltration, elevated expression of KIR2DL1, LGALS9, TNFRSF18, and TNFRSF4, increased sensitivity to imatinib and axitinib, resistance to multiple chemotherapeutics, and reduced Fusobacteria and Tenericutes abundance. HAAO, ALDH2, and lymph node stage were identified as independent prognostic factors and were used to develop a predictive nomogram. We identified a Trp metabolism-associated fibroblast population in the ESCC tumor microenvironment (TME) and developed a five-gene TrpG signature for prognostic prediction in ESCC patients.
    Journal • Gene Signature • IO biomarker
    |
    ALDH2 (Aldehyde Dehydrogenase 2 Family Member) • TNFRSF4 (TNF Receptor Superfamily Member 4) • TNFRSF18 (TNF Receptor Superfamily Member 18) • AGRN (Agrin) • KIR2DL1 (Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Long Cytoplasmic Tail 1) • LGALS9 (Galectin 9) • MAOA (Monoamine Oxidase A)
    |
    imatinib • axitinib
    7ms
    Molecular Interactions Between NK Cells and Acute Leukemic Cells: KIR2DL5 Drastically Limits NK Cell Responses. (PubMed, J Clin Immunol)
    Furthermore, molecular interactions between NK cells and leukemic cells influence NK cell responses, particularly the inhibitory KIR2DL5-PVR axis. The integration of these data is of importance for the optimization of NK cell-based immunotherapies, as the selection of NK cell donors represents a key parameter for the improvement of these therapies.
    Journal • IO biomarker
    |
    B3GAT1 (Beta-1,3-Glucuronyltransferase 1) • KIR2DL1 (Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Long Cytoplasmic Tail 1) • KLRC1 (Killer Cell Lectin Like Receptor C1)
    8ms
    Analyses of peripheral blood NK cells in response to anti-PD-1 therapy in metastatic melanoma patients. (PubMed, Clin Immunol)
    In MM patients with disease control, contrary to DP patients blocking of PD-1 inhibitory molecule may increase NK cell cytotoxicity through enhancement of NK cell degranulation and activating receptor expression. Therefore, our findings show that NK cells and their receptors in MM patients may be potential biomarkers of response to Pembrolizumab.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    BRAF (B-raf proto-oncogene) • CD14 (CD14 Molecule) • LAMP1 (Lysosomal Associated Membrane Protein 1) • KIR2DL1 (Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Long Cytoplasmic Tail 1) • NKG2D (killer cell lectin like receptor K1)
    |
    BRAF wild-type
    |
    Keytruda (pembrolizumab)
    10ms
    KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT Children (clinicaltrials.gov)
    P2, N=50, Enrolling by invitation, Michael Pulsipher | Trial completion date: Aug 2024 --> Dec 2025 | Trial primary completion date: Aug 2024 --> Nov 2025
    Trial completion date • Trial primary completion date • IO biomarker
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • KIR2DL1 (Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Long Cytoplasmic Tail 1)
    11ms
    Spatial statistics of submicron size clusters of activating and inhibitory Natural Killer cell receptors in the resting state regulate early time signal discrimination. (PubMed, bioRxiv)
    Thus, spatial statistics of submicron-sized NKR clusters in the resting state provide a lever for distinguishing self from non-self. The results suggest spatial organization of receptors in the resting state in may modulate signal discrimination in immune cells.
    Journal
    |
    KIR2DL1 (Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Long Cytoplasmic Tail 1) • NKG2D (killer cell lectin like receptor K1)
    1year
    Isolation and characterization of primary NK cells and the enrichment of the KIR2DL1+ population. (PubMed, Methods Cell Biol)
    The current protocol provides an NK isolation technique to study the signaling pathways downstream to the Killer cell immunoglobulin-like receptors (KIR) that serve as key human NK cell function regulators. This procedure enables investigating mechanisms specific to individual KIRs to improve our understanding of NK cell function in health and disease.
    Journal
    |
    KIR2DL1 (Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Long Cytoplasmic Tail 1) • KIR2DS2 (Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Short Cytoplasmic Tail 2)
    1year
    Differential Role of NKG2A/HLA-E Interaction in the Outcomes of Bladder Cancer Patients Treated with M. bovis BCG or Other Therapies. (PubMed, Biomedicines)
    The MM genotype was associated with higher counts of circulating CD56bright, fewer KIR2DL1/L2+ NK cells, and lower NKG2A expression, but not with differential in vitro NK cell functionality. The HLA-B -21M/T is independently associated with BC patient outcomes and can help to optimize the use of new immunotherapies in these patients.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-E (Major Histocompatibility Complex, Class I, E) • CD80 (CD80 Molecule) • CD86 (CD86 Molecule) • KIR2DL1 (Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Long Cytoplasmic Tail 1) • KIR2DS2 (Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Short Cytoplasmic Tail 2) • KLRC1 (Killer Cell Lectin Like Receptor C1) • NKG2D (killer cell lectin like receptor K1)